Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 6901-6910 Newer>

The Motley Fool November 24, 2010 Sean Williams	ViroPharma: Bargain or Value Trap? Generic competition and production issues are major red flags.
The Motley Fool November 24, 2010 Brian Orelli	A Manly FDA Approval Eli Lilly has something to be thankful for this week; the Food and Drug Administration approved Axiron, its testosterone replacement therapy.
The Motley Fool November 24, 2010 Brian Orelli	Yay! We Don't Have to Pay an 18.5% Penalty Genzyme moves one step closer to a comeback. The company announced today that it had met its deadline for moving the fill-and-finish activities for drugs sold in the U.S. out of its beleaguered Allston, Mass., plant.
The Motley Fool November 23, 2010 Brian Orelli	Less of a Poke in the Eye Regeneron Pharmaceuticals was up nearly 20% yesterday after the drugmaker announced the results for two phase 3 trials testing VEGF Trap-Eye in wet AMD patients.
The Motley Fool November 23, 2010 Seth Jayson	Here's How Pfizer May Be Failing You With recent trailing twelve month margins all below historical averages, Pfizer has some work to do.
The Motley Fool November 23, 2010 Jared Cummans	Tuesday's ETF to Watch: Medical Devices Fund (IHI) With Medtronic's earnings report set for today, the iShares Dow Jones U.S. Medical Devices Index Fund should be active in trading.
Chemistry World November 22, 2010 Akshat Rathi	Irish drug industry fears bailout tax terms Any increase in Ireland's corporation tax rate as part of a financial bailout could hurt the country's rapidly expanding pharmaceutical industry, currently its largest contributor to corporation tax.
The Motley Fool November 22, 2010 Brian Orelli	Let's Call It a Partial Victory Merck's Vytorin works better than a placebo. Unfortunately, it may be too little and too late to do anything about the sales cut that Vytorin has taken over the past few years.
The Motley Fool November 22, 2010 Brian Orelli	Pfizer's Mixed Bag Pfizer had a mixed bag of clinical trial results at the end of last week. And probably the company would have rather seen the results flip-flopped.
The Motley Fool November 22, 2010 Travis Hoium	Regeneron Pharmaceuticals Shares Popped: What You Need to Know Regeneron Pharmaceuticals shares jumped 16% today after the company announced results from VEGF Trap-Eye testing.
<Older 6901-6910 Newer> Return to current articles.